Inositol monophosphatase is a potential drug target for developing lithium-mimetic agents for the treatment of bipolar disorder. Enzyme-based assays have been traditionally used in compound screening to identify inositol monophosphatase inhibitors. A cell-based screening assay in which the compound needs to cross the cell membrane before reaching the target enzyme offers a new approach for discovering novel structure leads of the inositol monophosphatase inhibitor. The authors have recently reported a high-throughput measurement of G-protein-coupled receptor activation by determining inositol phosphates in cell extracts using scintillation proximity assay. This cell-based assay has been modified to allow the determination of inositol monophosphatase activity instead of G-protein-coupled receptors. The enzyme is also assayed in its native form and physiological environment. The authors have applied this cell-based assay to the high-throughput screening of a large compound collection and identified several novel inositol monophosphatase inhibitors. (Journal of Biomolecular Screening 2004:132-140) Key words: inositol monophosphatase, bipolar disorder, phosphatidylinositol turnover, IP 3 assay, cell-based enzyme assay 3 H-inositol. In the past 10 years, several laboratories have worked on a number of IMPase inhibitors, including natural products, 13,14 inositol phosphate-based compounds, 15,16 and others. 17,18 However, all these compounds were not sufficiently active in vivo, mainly due to their low bioavailability and poor permeability across the 132 www.sbsonline.org
INTRODUCTION
I T IS WELL KNOWN THAT MANY NEUROTRANSMITTERS and peptides activate phospholipase C (PLC) by binding to the specific G-protein-coupled receptors and growth factor receptors, which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP 2 ) to form 2 second messengers, inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 , in turn, increases intracellular Ca 2+ via activation of the IP 3 receptor, a receptor-operated Ca 2+ channel located on the endoplasmic reticulum membrane, whereas DAG activates protein kinase-C. IP 3 is then quickly inactivated by a series of phosphatases, including inositol monophosphatase (IMPase), and the resulting inositol is then recycled back into the cell membrane. IMPase is a key enzyme in the pathways for both the inositol de novo synthesis from glucose-1-phosphate and the inositol recycling process, that is, phosphatidylinositol (PI) turnover ( Fig. 1.) . 1, 2 Bipolar disorder is a chronic illness that affects approximately 1% of the population, and most patients require lifetime therapy. 3, 4 Lithium has been used in the treatment of bipolar disorder in the past 50 years, but it has a narrow therapeutic window. At the therapeutic plasma concentration (0.5 to 1 mM), it has several side effects such as thirst, weight gain, tremor, polyuria, and memory problems, but at > 2 mM plasma concentration, toxic effects occur, including nausea, vomiting, and even convulsion. It has been known that lithium inhibits a set of enzymes, and many of them may link to its adverse and toxic effects. Although the mechanism of action for lithium therapy is still not fully understood, inhibition of IMPase and the subsequent depletion of the inositol pool in living cells have been implicated as the primary therapeutic benefit of lithium treatment. 5, 6 Therefore, a selective IMPase inhibitor might be a good drug candidate to replace lithium for the treatment of bipolar disorder.
Human IMPases have been cloned, and the crystal structures have been published. [7] [8] [9] [10] [11] IMPase is the enzyme in the brain responsible for the hydrolysis of inositol monophosphates to release free myo-inositol. 2 Traditionally, 2 types of enzyme assays have been available for the measurement of IMPase activity. 12 The colorimetric assay uses malachite green reagent to measure released free phosphate, whereas the radiometric assay uses an anion chromatography step to separate 3 H-inositol-1-phosphate from cell membrane. To search for new classes of lead compounds that are able to efficiently cross the cell membrane, we have applied a novel approach for the high-throughput screening (HTS) of a large compound collection. Here we report the successful discovery of novel IMPase lead compounds by using a cell-based, scintillation proximity, PI turnover assay in a fully automated format.
MATERIALS AND METHODS
Yttrium silicate (YSi) scintillation proximity assay (SPA) beads as a 100-mg/mL suspension in water (No. RPNQ0013, untreated beads) were purchased from Amersham Biosciences (Piscataway, NJ). Carbachol, atropine, and LiCl were obtained from Sigma (St. Louis, MO). HANKS-balanced salt solution was purchased from Invitrogen (San Diego, CA), and inositol-free Dulbecco's modified Eagle's medium (DMEM) cell culture medium was obtained from ICN Biomedicals, Inc. (Aurora, OH). 3 H-myo-inositol T24 cells stably expressing the human M1 muscarinic receptor (M1-T24) were cultured in DMEM Glutamax medium (Invitrogen/GIBCO) supplemented with 10% fetal bovine serum (FBS) (Hyclone), 100 U/mL penicillin-G, 100 µg/mL streptomycin, and 0.4 mg/mL G-418 sulfate (Invitrogen/GIBCO) at 37°C with 5% CO 2 in a humidified atmosphere. The preparation and characterization of this cell line will be described elsewhere.
Cell culture and labeling with
M1-T24 cells were plated in the black 384-well tissue culturetreated plate with a clear bottom (Corning, No. 3701) at a density of 3000 cells/well in 20 µL and incubated at 37°C with 5% CO 2 in a humidified atmosphere for 20 to 24 h. Cells were washed once with 50 µL/well of HANKS-balanced salt solution using an Embla-384 plate washer (Molecular Devices, Sunnyvale, CA). After the second aspiration, 20 µL inositol-free DMEM containing 2 mM L-glutamine, 0.1% BSA, and 0.2 µCi [ 3 H]myo-inositol (NEN, specific activity of 70 to 80 Ci/mmol) was added to each well using a Multidrop liquid handler (Labsystems). The cells were then cultured at 37°C with 5% CO 2 in a humidified atmosphere overnight, typically 16 h.
Automated SPA assay to measure accumulated 3 H-inositol phosphates A customized robotic system (Robocom/CRS robot, Burlington, ON, Canada) was used for this automated screening in the 384-well plate format. This robot is equipped with a 6-meter linear track and a CRS robotic arm, as well as the liquid handlers, cell incubators, cell washers, and scintillation plate readers (Fig.  2) . The 3 H-labeled cells in the 384-well assay plates were loaded into the cell incubators on the robot. One assay plate was picked out of the incubator every 12 min, and 0.3 µL of the 500-µM compound in DMSO solution or 1 M LiCl (as a positive control) was added to each well containing 20-µL cells prelabeled with 3 Hinositol using a Cybi-Disk 384-well pipette (Cybio, Inc., Woburn, MA), followed by an addition of 10 µL of 3-mM carbachol, a muscarinic receptor agonist, using a Multidrop (Labsystems). The assay plate was returned to the cell incubator for a 30-min incubation at 37°C, and then 10 µL of 0.4-mM atropine, a muscarinic receptor antagonist, was added to each well with a further incubation at 37°C for 10 min. Then, the solution in the assay plate was aspirated with an Embla cell washer, and 40 µL of 10-mM formic acid was added using a Multidrop to each well followed by a 20-min incubation at room temperature to release 3 H-inositol phosphates ( 3 H-IPs) from the cells. Using a Cybi-well 384-well pipette, the 25-µL resulting solution after formic acid treatment was transferred to a white 384-well plate (BD Biosciences, No. 353232), and 10 µL of 25-mg/mL Ysi SPA beads were added with a Cybi-well pipette and a bead mixer, which kept the beads in suspension. The plate was agitated in a mixer for 5 min, and then beads were allowed to settle for 2 h before the assay plate was counted for 0.5 min per well in 1 of 2 scintillation plate readers on the robot (Topcount, PerkinElmer, Boston). Plates were not covered or sealed during the scintillation counting.
Separation by high-performance liquid chromatography (HPLC) and detection of inositol phosphates
Cells labeled with 3 H-inositol and treated with compounds and carbachol as described above in 96-well plates were lysed for 20 min at room temperature with 100 µL of 10-mM formic acid per well. Samples from 6 similarly treated wells were pooled and frozen. After thawing, samples were spun at 16,000 g for 5 min at room temperature, and 400 µL of the sample was transferred to a new tube. The sample was evaporated to dryness in a Savant DNA 120 Speed Vac, taken up in 100 µL water, centrifuged, transferred to a sealed vial, and held at 7°C until analysis. These steps served to remove formic acid and to concentrate the sample. Samples were chromatographed on a 250 × 2-mm AS11 column (with a 2mm AG11 guard column, both from Dionex) at 30°C using a Dionex 2-mm microbore system with GS50 pumps, a LEAP HTC-PAL autosampler equipped with a steel needle Hamilton syringe, and a Dionex LC30 chromatography oven. The solvent was water, and retained compounds were eluted with linear gradients of NaOH at 0.5 mL/min: 0 to 8 min, 4 mM; 8 to 13 min, 30 mM; 13 to 23 min, 53 to 63 mM; 23 to 25 min, 100 mM; and 25 to 33 min, 4 mM. Analytes were detected in series by a Dionex ED50 electrochemical detector equipped with a Dionex 2-mm ASRS-Ultra suppressed conductivity detector in external water mode and an IN/ US Systems model-3 βRAM radio-HPLC detector equipped with a 200-µL flow cell.
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Data analysis
EC 50 and IC 50 values were calculated from concentrationresponse curves by a nonlinear regression analysis using Prism software (GraphPad Software, San Diego, CA). The screening results were analyzed using customized HTS data analysis software, and the data were stored in a customized database.
RESULTS AND DISCUSSION
Assay design and assay validation
M1-T24 cells were preloaded with 3 H-inositol to label the inositol phospholipids on the cell membrane, and carbachol was used to stimulate the M1 receptor. This results in the activation of PLC, which hydrolyzes 3 H-PIP 2 to form 3 H-IP 3 and 3 H-inositol monophosphates ( 3 H-IP 1 ). IP 3 is also phosphorylated to IP 4 , which is dephosphorylated as illustrated in Figure 1 . Then, 3 H-inositol monophosphates are converted to 3 Hinositol by IMPase. In a normal cell, when the inhibitors of IMPase and inositol polyphosphatase (IPPase) are absent, only a small portion of 3 H-IPs, including 3 H-IP 1 , 3 H-IP 2 , and 3 H-IP 3 , can be detected due to the rapid cycling of the PI turnover process. The basal response in this cell-based IMPase assay reflects a small amount of 3 H-IPs after carbachol stimulation in the absence of the IMPase inhibitor. However, in the presence of lithium or compounds that inhibit the IMPase activity, 3 H-IPs are accumulated. Total 3 H-IPs released from cells after the 10-mM formic acid treatment can be measured by separating 3 H-IPs from 3 H-inositol. In the traditional assay, a step of anion exchange chromatography is required for this separation, which makes the throughput of compound screening relatively low, although it can be formatted into the 96-well plate. 19, 20 A SPA-based assay for the measurement of guanine protein-coupled receptor (GPCR)-induced PI turnover in the 384well plate format has recently been developed with relatively high throughput. 21 Here, we applied this assay to detect inositol phosphatase inhibition in whole cells for the automated compound screening. The accumulated negatively charged 3 H-IPs stimulated by carbachol in the presence of lithium or other IMPase inhibitors were captured by the positively charged SPA beads and measured in a scintillation plate reader. Carbachol concentrationdependently stimulated the accumulation of 3 H-IPs in the presence of 10 mM LiCl, and the EC 50 value for carbachol was 439 nM. Atropine, an inhibitor of muscarinic receptors, dose-dependently inhibited the response induced by 1 µM carbachol (IC 50 = 1.17 nM) (Fig. 3a,b) . These EC 50 and IC 50 values were similar to those reported elsewhere. 21 The assay in this format has been used as a functional screening for the Gq-coupled GPCRs (data not shown).
To screen the compound collection for IMPase inhibitors, a high concentration of carbachol (1 mM) was applied to all wells in the assay plate to stimulate the cells for 30 min in the presence of the 5-µM compound or 10 mM LiCl (as a standard inhibitor for the control response), followed by a 10-min incubation with 100 µM atropine. This addition of atropine effectively arrested PI hydrolysis by antagonizing the action of carbachol, which, in the absence of inositol phosphatase inhibitors, allowed degradation of inositol phosphates to background levels. This step greatly reduces the assay basal signal and increases the signal-to-basal ratio, thus increasing the Z factor 21 associated with the assay.
Robotic assay development
This cell-based screening assay involved 2 cell wash steps with one prior to 3 H-inositol incubation and another one before cell lysis. The entire cycle for this assay was approximately 19 to 20 h for each plate. To format this complicated assay into an efficiently automated robotic assay, the step for cell labeling with 3 H-inositol was undertaken as a batch operation, with 50 to 60 plates labeled in the early morning and late afternoon, respectively. The robotic screening started from the addition of compounds followed by carbachol stimulation. The cycle for each plate on the robot was then reduced to approximately 3 h. The activities of LiCl (data not shown here) and L-690488, a known prodrug of an IMPase inhibitor, were similar in the robotic assay compared with those determined from the manual assay (Fig. 4a) . The effect of DMSO on this assay was insignificant at the concentration of 1% or less (Fig.  4b) .
For the robotic screening in the 384-well plate format, 10 mM LiCl was added to the first 32 wells (in columns 1 and 2) as the control response, and compounds were added to next 320 wells (in columns 3 to 22). The last 32 wells were used as a basal response H-inositol were stimulated with 1 mM carbachol in the presence of 10 mM LiCl for 30 min. The cells were then lysed, and the accumulated 3 H-inositol phosphates ( 3 H-IPs) due to the inhibition of inositol monophosphatase (IMPase) were captured by the yttrium silicate scintillation proximity assay (SPA) beads, which were counted in a scintillation plate reader. (a) Carbachol concentration-dependently increased the accumulation of without addition of LiCl or compounds. A set of 384-well plates, with an addition of DMSO instead of compounds, was initially used to validate this cell-based IMPase assay on the robot. The signal-to-basal ratio (the maximum response of 1 mM carbachol in the presence of 10 mM LiCl to the carbachol response in the absence of LiCl) was usually 15-to 30-fold, and the Z factor was 0.5 to 0.7 in these plates. Although the signal was doubled over the time during 24-h screening due to the increased incorporation of 3 H-inositol into the cell membrane, the activity of the positive control, LiCl, remained unchanged (EC 50 =~300 µM). The 3-sigma value (3 times the standard deviation, calculated from 320 wells with DMSO solution) was 4% to 8%. This indicated that a weak IMPase inhibitor would be detectable in this screening.
During the screening assay validation, we encountered random bursts of signal in the wells without compounds in a portion of assay plates (Fig. 5a,c) . This had the potential to significantly increase the false-positive rate during compound screening. We assumed that this artifact was caused by accumulation of static on the plate. In fact, this false signal disappeared after the assay plate was wiped with a wet paper towel immediately before being placed into a scintillation plate reader for scintillation counting. This simple measure eliminated the unwanted signal caused by static ( Fig.  5b,d ). However, it was not practically feasible to wipe each plate during the robotic screening. Instead, a 3M Mini Air Ionizer commonly used in the semiconductor industry was installed near the scintillation plate reader, which continuously blew a stream of ionized air to neutralize static on the surface of each assay plate before entering the plate reader. The majority of the false positives caused by static were then effectively eliminated after the addition of this ionizer fan.
Primary screening of a compound collection
A large compound collection was screened in this cell-based IMPase assay using a screening robot with a throughput of 100 to 120 plates per day in a 384-well plate format. The signal-to-basal ratio was usually from 10-to 30-fold, and the coefficient of variation (CV) of the control lithium response in each assay plate typically was 20% to 30%, which is in the range of most cell-based screenings we have performed (Fig. 6a,b) . The gradual increase in the control lithium response from 2000 to 5000 cpm was due to the increased 3 H-inositol incorporation into the cell membrane because the compound screening progressed continuously within a period of 24 h, and the labeling of 3 H-inositol was completed in a 1h batch operation. However, the activity of the standard IMPase inhibitor, LiCl, did not change significantly with the increase of the 3 H-inositol incorporation into the cell membrane. The IC 50 value of LiCl was 380 µM in the first plate (slope = 1.65) and 393 µM in the last plate (slope = 1.61).
A total of 456 compounds with activity greater than 16% of lithium response were chosen as "primary hits" from the screening of a large compound collection. The assay signal ( 3 H-IPs) was increased when a compound inhibited IMPase activity, similar to that of lithium response. This is due to the fact that 3 H-IPs is accumulated in the presence of these IMPase inhibitors and measured by the SPA assay. For the hit selection, the compounds with activity greater than 16% lithium response were chosen because 3sigma (3 times the standard deviation) from the entire screening campaign was 15%. These 456 compounds were retested in triplicate in the same assay format at a 5-µM concentration, and the activities of 4 compounds were confirmed. These confirmed compounds have not been identified previously in the enzyme-based screening. The structures of these confirmed compounds are related and distinct from the known IMPase inhibitors. It is believed that this novel template of compound structure has great potential as the IMPase inhibitor for the medicinal chemistry program. The low hit rate from primary screening was expected because the charged compounds or the compounds with poor membrane permeability would not be active in this cell-based assay format. In addition, some of the compounds might lose their activity inside cells due to the modifications by intracellular enzymes. These compounds, which are impermeable to cell membrane or lose activity inside of cells, are not a suitable drug candidate because an IMPase inhibitor is eventually required to be active in cells and in vivo, no matter how potent it is at the enzyme level. Therefore, this assay gives a better prediction of in vivo activity of lead compounds, where cell membrane permeability, metabolizing enzymes, and so forth are encountered by compounds during further testing. Although this screening did not identify a large number of compounds as the IMPase inhibitors, the leads discovered from the cell-based screening should have a better opportunity to be developed into a drug candidate compared with those discovered from the enzyme assay.
Subsequently, the hit rate of primary screening for this assay was very low (0.05%). The confirmation rate for primary hits was not high as well, despite special measures that were taken during the HTS campaign to reduce the number of false positives. This could be due to the low cutoff (> 16% of lithium response) for se- lecting the primary hits, which might be in the noise range of this screening assay. Indeed, the hit rate of 0.05% was similar to the one we often observed as the false-positive rate in the no-compound wells in many other cell-based screenings (data were not shown).
The occasional buildup of static in the assay plates, despite the antistatic measure during the robotic screening, might be the major reason for those nonconfirmed "hits" as we had rescreened a portion of compound plates that contained the nonconfirmed hits but failed to repeat the results (data not shown).
Hits follow-up
Three available compounds in powder form from 4 confirmed hits were retested in the same cell-based assay and their potencies determined. The maximum activities of these 3 compounds were approximately a half of the lithium response (Fig. 7a) , and the IC 50 values were 2 to 4 µM (Fig. 7b ). In the absence of carbachol, all 3 compounds were not active, which excluded the possibility of mechanism-based false positives such as direct activation of other GPCRs, G-proteins, or PLC. This cell-based assay uses the SPA method to measure the total soluble inositol phosphate mass. A positive signal indicates the accumulation of inositol phosphates, but it does not distinguish which specific inositol phosphate is accumulated. To identify which enzyme is inhibited by the compounds, we used HPLC to resolve the 3 H-inositol phosphates that accumulated when the cells were treated with carbachol and either lithium or the confirmed compounds ( Fig. 8 ). Lithium inhibits both IMPase and IPPase (see Fig. 1 ) in the PI turnover cycle. Consistent with this, 10 mM LiCl caused accumulation of IP 1 , IP 2 , and IP 3 isomers in carbachol-challenged M1-T24 cells. However, only inositol monophosphates were accumulated in carbacholstimulated M1-T24 cells treated with the 10-µM compound 2, the most potent hit. This implies that compound 2 is blocking IMPase selectively over the other inositol phosphatases. The cell extracts after the treatments of compound 1 and compound 3, along with carbachol stimulation, showed the same HPLC profile as that of compound 2, indicating that both of them inhibited IMPase in the cell-based assay (data not shown here). The measurements of activities of these compounds in isolated enzymes are still in progress, and the results will be presented in a follow-up report.
CONCLUSION
A novel cell-based screen in a 384-well plate and SPA format has been developed and applied for the screening of a large compound collection to identify inositol phosphatase inhibitors. The assay has been automated in a robot with a daily screening throughput of 100 to 120 plates in a 384-well plate format. The advantages of this screening assay, compared with the traditional enzyme-based assay for inositol phosphatase inhibitors, are a high throughput and the ability to identify cell membrane-permeable compounds. Several novel structures of the IMPase inhibitor have been discovered after the HTS of a large size of the compound collection using this cell-based inositol phosphatase assay. The assay signal was calculated as the median of the first 32 wells treated with 10 mM LiCl and stimulated by 1 mM carbachol, followed by 100 µM atropine. The basal response was calculated as the median of the next 320 wells in which the 5-µM compound was added. The basal response was similar to that from the last 32 wells, without the addition of lithium or compounds. (b) Signal-to-noise ratio (S/N) and coefficient of variation (CV) of each assay plate in this 88-plate run. The S/N (filled circles) was calculated by the median of the assay signal from 32 wells, with 10 mM LiCl divided by the median of responses from 320 wells containing 5-µM compounds in each assay plate. S/N was 16-to 44-fold in this robotic run. CV (open triangles) was calculated as the percentage of the standard deviation of the assay response in 32 wells treated with 10 mM LiCl divided by the average value of these 32 wells. H-inositol phosphates in cells treated with LiCl or compound 2. M1-T24 cells were plated in a 96-well plate and labeled with 5 µCi/well of 3 Hinositol for 16 h in assay medium (inositol-free Dulbecco's modified Eagle's medium [DMEM] with 2 mM L-glutamine and 0.3% w/v bovine serum albumin). Cells were washed with 2 × 200-µL assay medium, and then the 150-µL assay medium per well was added. Compound in DMSO or LiCl in water was added to the plate at 37°C in 2 µL, followed 1 min later by carbachol in a 50-µL assay medium. The indicated concentrations Cells were incubated for 20 min at 37°C before extraction and analysis of 3 H-inositol phosphates by HPLC, as described in Materials and Methods. Free inositol appeared at the solvent front and is not shown for clarity. Peaks were identified by comparison to authentic nonradiolabeled inositol phosphate standards that were detected by conductivity.
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